Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 25 June 2012 | By Ansis Helmanis
Brazil's National Health Surveillance Agency (ANVISA) published a new proposed rule on medicines used as reference products for generic equivalents (RDC No. 35/12) on 19 June 2012.
According to the proposal, the List of Reference Medicines shall consist of three groups of drugs:
Drugs that have been withdrawn from the market or have safety, efficacy or quality concerns will be excluded from the List.
RDC No. 35/12
More Breaking News from RegLink
Tags: Generic, pharmaceutical, brazil, drug, Biosimilars, Biologics